{"url_path":"/sec/asbp/8-k/2026-07-20/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/1847345/0001493152-26-033942-index.html","accession_number":"0001493152-26-033942","cik":"0001847345","ticker":"ASBP","issuer_name":"Aspire Biopharma Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1847345/0001493152-26-033942-index.html","primary_entity_key":"0001847345","primary_entity_name":"Aspire Biopharma Holdings, Inc."},"word_count":342,"has_tables":true,"body_markdown":"false\n0001847345\n\n0001847345\n\n2026-07-20\n2026-07-20\n\n0001847345\n\nASBP:CommonStockParValue0.0001PerShareMember\n\n2026-07-20\n2026-07-20\n\n0001847345\n\nASBP:WarrantsEachExercisableForOneShareOfCommonStockMember\n\n2026-07-20\n2026-07-20\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**Washington,\nD.C. 20549**\n\n \n\n**FORM\n8-K**\n\n \n\n**CURRENT\nREPORT**\n\n \n\n**Pursuant\nto Section 13 OR 15(d) of the**\n\n**Securities\nExchange Act of 1934**\n\n \n\nDate\nof Report (Date of earliest event reported): **July 20, 2026**\n\n \n\n**Aspire\nBiopharma Holdings, Inc.**\n\n(Exact\nName of Registrant as Specified in Its Charter)\n\n \n\n**Delaware**\n \n**001-41293**\n \n**33-3467744**\n\n(State\nor other jurisdiction\n\nof\nincorporation)\n\n \n\n(Commission\n\nFile\nNo.)\n\n \n\n(I.R.S.\nEmployer\n\nIdentification\nNo.)\n\n \n\n**23150\nFashion Drive, Suite 232**\n\n**Estero,\nFlorida 33928**\n\n(Address\nof Principal Executive Offices)\n\n \n\n**(908)\n987-3002**\n\n(Registrant’s\nTelephone Number)\n\n \n\n**194\nCandelaro Drive, # 233**\n\n**Humacao,\nPR 00791**\n\n(Former\nName or Former Address, if Changed Since Last Report)\n\n \n\nCheck\nthe appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under\nany of the following provisions (see General Instruction A.2. below):\n\n \n\n☐\nWritten communications\npursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n \n\n☐\nSoliciting material pursuant\nto Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n \n\n☐\nPre-commencement communications\npursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n \n\n☐\nPre-commencement communications\npursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities\nregistered pursuant to Section 12(b) of the Act:\n\n \n\nTitle\nof each class\n \nTrading\nSymbol(s)\n \nName\nof each exchange on which registered\n\n**Common stock, par value\n$0.0001 per share**\n \n**ASBP**\n \n**The Nasdaq Stock Market\nLLC**\n\n**Warrants, each exercisable\nfor one share of common stock**\n \n**ASBPW**\n \n**The Nasdaq Stock Market\nLLC**\n\n \n\nIndicate\nby check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405\nof this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging\ngrowth company ☒\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐"}